Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
CE

OTC · CERO

CERo Therapeutics Holdings, Inc.

Healthcare · Biotechnology

$0.01

Up+$0.00 (+0.00%)

Updated Sep 12, 2026, 8:42 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
108.48K
P/E ratio
-0.01
Dividend yield
0.00%
52-week range
$0.03 – $5.72
Volume
96.28K
Avg. volume
2.55M

Price performance

CERO price history

1M range · 0 trading sessions · Daily adjusted prices

CERO does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CERO news

The latest Smart Investors Daily articles mentioning CERO.

Stock researchCompany · Overview

CERO research

Overview

Company profile and research snapshot.

Company profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CERO recent ratings
DateFirmRatingTarget
Nov 18, 2025D. Boral CapitalHold—
Nov 3, 2025Maxim GroupHold—
Oct 30, 2025D. Boral CapitalBuy—
Oct 22, 2025D. Boral CapitalBuy—
Oct 13, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

globenewswire.com · Dec 2, 2025

CERo Therapeutics Announces Trading on OTCQB Market

Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB : CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, announces its shares will be available to trade on the OTCQB market under the ticker symbol CERO effective today, December 2, 2025 as of 8:00AM ET.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By